Although it is likely that multiple cells contribute to the increased IL-17A and IL-17F production observed during NAFLD pathogenesis, the identification of the major hepatic IL-17RA ligand producers may result in specific treatment options that do not compromise the overall systemic IL-17 response. The gene discussed is IL17RA; the disease is metabolic dysfunction-associated steatotic liver disease.